- Publikační typ
- abstrakt z konference MeSH
x
x
- MeSH
- alfa blokátory farmakologie terapeutické užití MeSH
- analýza moči MeSH
- hyperplazie prostaty * diagnóza patofyziologie terapie MeSH
- inhibitory 5-alfa-reduktasy farmakologie terapeutické užití MeSH
- inhibitory fosfodiesterasy 5 farmakologie terapeutické užití MeSH
- lidé MeSH
- miniinvazivní chirurgické výkony metody MeSH
- symptomy dolních močových cest diagnóza terapie MeSH
- transuretrální resekce prostaty metody využití MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- abstrakt z konference MeSH
Testicular cancer represents between 1% and 1.5% of male neoplasms and 5% of urological tumours in general. There has been significant increase of its incidence during last 40 years, with reference to individual countries. However, testicular tumours show excellent cure rates. The main factors contributing to this are: careful staging at the time of diagnosis; adequate early treatment based on chemotherapeutic combinations, with or without radiotherapy and surgery; and very strict follow-up and salvage therapies. Radical orchiectomy is the standard treatment for testis tumours. Testis-sparing surgery has recently been proposed as an alternative option in selected cases. According to the 2010 EAU Guidelines testis-sparing surgery can be attempted in special cases with all the necessary precautions. In synchronous bilateral testicular tumours, metachronous contralateral tumours, or in a tumour in a solitary testis with normal pre-operative testosterone levels. Organ preserving surgery can be performed when the tumour volume is less than 30 % of the testicular volume and surgical rules are respected. The aim of our study was to assess testis-sparing surgery for testicular tumours in adult patients with solitary testes as well as in selected patients with healthy contralateral testes.
